Bionano Genomics Subsidiary Says MolDX Issues Proposed LCD For Genome-Wide Molecular Methodologies For Detection Of Copy Number Alterations And Structural Variants In Hematologic Neoplasms
Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that MolDX, a program that assesses molecular
A big government health program said it would review whether to cover Bionano's blood cancer test. This could mean more patients can use the test if the program approves it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.